These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12194991)

  • 1. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer.
    Lopez-Beltran A; Luque RJ; Mazzucchelli R; Scarpelli M; Montironi R
    J Clin Pathol; 2002 Sep; 55(9):641-7. PubMed ID: 12194991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urothelial changes induced by therapeutic procedures for bladder cancer. A review.
    Mazzucchelli R; Barbisan F; Tarquini LM; Streccioni M; Galosi AB
    Anal Quant Cytol Histol; 2005 Feb; 27(1):27-34. PubMed ID: 15794449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bladder treatment. Immunotherapy and chemotherapy.
    Lopez-Beltran A
    Urol Clin North Am; 1999 Aug; 26(3):535-54. PubMed ID: 10494289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iatrogenic changes in the urinary tract.
    Lopez-Beltran A; Paner GP; Montironi R; Raspollini MR; Cheng L
    Histopathology; 2017 Jan; 70(1):10-25. PubMed ID: 27960233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iatrogenic pathology of the urinary bladder.
    Lopez-Beltran A; Montironi R; Raspollini MR; Cheng L; Netto GJ
    Semin Diagn Pathol; 2018 Jul; 35(4):218-227. PubMed ID: 29576423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urothelial changes induced by therapeutic procedures for bladder cancer.
    Lopez-Beltran A
    Anal Quant Cytol Histol; 2006 Dec; 28(6):339. PubMed ID: 17220148
    [No Abstract]   [Full Text] [Related]  

  • 7. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
    Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
    Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma.
    Sonpavde G; Bellmunt J
    Nat Rev Urol; 2016 Jun; 13(6):306-7. PubMed ID: 27071455
    [No Abstract]   [Full Text] [Related]  

  • 10. What happens if nothing happens?--History of an untreated urothelial carcinoma of the bladder.
    Gerullis H; Ecke TH; Wishahi M; Georgas E; Eimer C; Otto T
    J Egypt Soc Parasitol; 2010 Dec; 40(3):789-96. PubMed ID: 21268545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
    Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab in urothelial bladder carcinoma.
    Hamilou Z; Lavaud P; Loriot Y
    Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexyl-aminolevulinate-mediated photodynamic therapy: how to spare normal urothelium. An in vitro approach.
    Vaucher L; Jichlinski P; Lange N; Ritter-Schenk C; van den Bergh H; Kucera P
    Lasers Surg Med; 2007 Jan; 39(1):67-75. PubMed ID: 17096415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.
    Hartmann A; Moser K; Kriegmair M; Hofstetter A; Hofstaedter F; Knuechel R
    Am J Pathol; 1999 Mar; 154(3):721-7. PubMed ID: 10079249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy.
    Lane Z; Epstein JI
    Am J Surg Pathol; 2008 Jan; 32(1):92-7. PubMed ID: 18162775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.
    Shanks JH; Iczkowski KA
    Histopathology; 2009 Jun; 54(7):885-900. PubMed ID: 19178589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.
    DiBianco JM; George AK; Su D; Agarwal PK
    Curr Opin Urol; 2015 Sep; 25(5):468-75. PubMed ID: 26125507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schistosomiasis and bladder cancer: similarities and differences from urothelial cancer.
    Zaghloul MS; Gouda I
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):753-63. PubMed ID: 22716492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroendocrine carcinoma of the bladder: A single centre retrospective study].
    Ayedi I; Abdelli I; Chaabouni H; Charfi S; Khanfir A; Toumi N; Mhiri N; Daoud J; Frikha M
    Cancer Radiother; 2016 Feb; 20(1):1-5. PubMed ID: 26762704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.